Abstract
Eight women who each experienced 4-8 episodes of Clostridium difficile-associated diarrhea were given a 2-week course of rifaximin therapy when they were asymptomatic, immediately after completing their last course of vancomycin therapy. Seven of the 8 patients experienced no further diarrhea recurrence. The patient who had a recurrence responded to a second course of rifaximin therapy, but rifaximin-resistant C. difficile was recovered after treatment. A controlled trial for treating recurrent Clostridium difficile-associated diarrhea appears to be warranted.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Adult
-
Age Factors
-
Aged
-
Clostridioides difficile / isolation & purification*
-
Diarrhea / drug therapy*
-
Diarrhea / microbiology
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Drug Therapy, Combination
-
Enterocolitis, Pseudomembranous / diagnosis
-
Enterocolitis, Pseudomembranous / drug therapy*
-
Female
-
Follow-Up Studies
-
Humans
-
Microbial Sensitivity Tests
-
Middle Aged
-
Prospective Studies
-
Rifamycins / administration & dosage*
-
Rifaximin
-
Risk Factors
-
Secondary Prevention
-
Severity of Illness Index
-
Treatment Outcome
-
Vancomycin / administration & dosage*
Substances
-
Rifamycins
-
Vancomycin
-
Rifaximin